William Blair Equities Analysts Decrease Earnings Estimates for Tempest Therapeutics, Inc. (NASDAQ:TPST)

Tempest Therapeutics, Inc. (NASDAQ:TPST) – Investment analysts at William Blair lowered their Q2 2024 earnings per share (EPS) estimates for shares of Tempest Therapeutics in a note issued to investors on Thursday, June 20th. William Blair analyst M. Phipps now expects that the company will earn ($0.56) per share for the quarter, down from their prior estimate of ($0.50). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.58) per share. William Blair also issued estimates for Tempest Therapeutics’ Q3 2024 earnings at ($0.45) EPS, Q1 2025 earnings at ($0.53) EPS, Q2 2025 earnings at ($0.62) EPS, Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($2.61) EPS, FY2026 earnings at ($4.09) EPS and FY2027 earnings at ($4.38) EPS.

Tempest Therapeutics (NASDAQ:TPST) last released its earnings results on Thursday, May 9th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.08.

Other analysts have also issued research reports about the company. Scotiabank started coverage on Tempest Therapeutics in a report on Thursday, March 14th. They set a “sector outperform” rating and a $13.00 price objective on the stock. Piper Sandler reissued an “overweight” rating and set a $8.00 price objective on shares of Tempest Therapeutics in a report on Friday. Finally, HC Wainwright restated a “buy” rating and set a $47.00 target price on shares of Tempest Therapeutics in a research report on Thursday. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $20.75.

Tempest Therapeutics Price Performance

Shares of NASDAQ:TPST opened at $2.03 on Monday. Tempest Therapeutics has a 1-year low of $0.17 and a 1-year high of $9.77. The firm has a market capitalization of $45.11 million, a PE ratio of -1.18 and a beta of -1.78. The business’s 50 day moving average is $3.24 and its 200-day moving average is $3.70. The company has a current ratio of 3.13, a quick ratio of 3.13 and a debt-to-equity ratio of 0.20.

Institutional Investors Weigh In On Tempest Therapeutics

An institutional investor recently raised its position in Tempest Therapeutics stock. Virtu Financial LLC increased its stake in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) by 69.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 28,574 shares of the company’s stock after purchasing an additional 11,689 shares during the period. Virtu Financial LLC owned approximately 0.13% of Tempest Therapeutics worth $112,000 as of its most recent SEC filing. 22.52% of the stock is currently owned by hedge funds and other institutional investors.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.